JP2022507103A5 - - Google Patents

Info

Publication number
JP2022507103A5
JP2022507103A5 JP2021525303A JP2021525303A JP2022507103A5 JP 2022507103 A5 JP2022507103 A5 JP 2022507103A5 JP 2021525303 A JP2021525303 A JP 2021525303A JP 2021525303 A JP2021525303 A JP 2021525303A JP 2022507103 A5 JP2022507103 A5 JP 2022507103A5
Authority
JP
Japan
Prior art keywords
corticosteroid
dose
hsd1 inhibitor
urinary
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507103A (ja
JP7472122B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046449 external-priority patent/WO2020106337A1/en
Publication of JP2022507103A publication Critical patent/JP2022507103A/ja
Publication of JP2022507103A5 publication Critical patent/JP2022507103A5/ja
Priority to JP2024063590A priority Critical patent/JP2024098991A/ja
Application granted granted Critical
Publication of JP7472122B2 publication Critical patent/JP7472122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525303A 2018-11-20 2019-08-14 コルチコステロイドを投与する方法 Active JP7472122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063590A JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769932P 2018-11-20 2018-11-20
US62/769,932 2018-11-20
PCT/US2019/046449 WO2020106337A1 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063590A Division JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Publications (3)

Publication Number Publication Date
JP2022507103A JP2022507103A (ja) 2022-01-18
JP2022507103A5 true JP2022507103A5 (cg-RX-API-DMAC7.html) 2022-08-23
JP7472122B2 JP7472122B2 (ja) 2024-04-22

Family

ID=70774135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525303A Active JP7472122B2 (ja) 2018-11-20 2019-08-14 コルチコステロイドを投与する方法
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Country Status (10)

Country Link
US (2) US12220412B2 (cg-RX-API-DMAC7.html)
EP (1) EP3883578A4 (cg-RX-API-DMAC7.html)
JP (2) JP7472122B2 (cg-RX-API-DMAC7.html)
CN (1) CN113329754A (cg-RX-API-DMAC7.html)
AU (2) AU2019384074B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009653A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120339A1 (cg-RX-API-DMAC7.html)
IL (2) IL319327A (cg-RX-API-DMAC7.html)
MX (2) MX2021005801A (cg-RX-API-DMAC7.html)
WO (1) WO2020106337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス，インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
BR112021015481A2 (pt) * 2019-02-08 2021-12-07 Sanofi Sa Otimização biotecnológica de micro-organismos para a 1,2-desidrogenação de esteroides
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
IL316907A (en) * 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS
AU2024348222A1 (en) * 2023-09-27 2026-04-16 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid-mediated diseases
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
GB0101447D0 (en) * 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
WO2003059267A2 (en) 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
ATE455547T1 (de) 2003-04-11 2010-02-15 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
ATE476425T1 (de) 2003-05-29 2010-08-15 Merck Sharp & Dohme Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
WO2005044192A2 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
BRPI0417687A (pt) 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
US7507832B2 (en) 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
WO2005097759A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
JP4993407B2 (ja) 2004-08-04 2012-08-08 大正製薬株式会社 トリアゾール誘導体
CN101014578B (zh) 2004-09-16 2011-01-19 安斯泰来制药有限公司 三唑衍生物或其盐
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
JPWO2006080533A1 (ja) 2005-01-31 2008-06-19 持田製薬株式会社 ３−アミノ−１，２，４−トリアゾール誘導体
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
KR20080016649A (ko) 2005-06-16 2008-02-21 화이자 인코포레이티드 Ｎ-(피리딘-2-일)-술폰아미드 유도체
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
WO2007021941A2 (en) 2005-08-16 2007-02-22 Icagen, Inc. Inhibitors of voltage-gated sodium channels
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
MX2008011723A (es) 2006-03-16 2008-09-26 Astellas Pharma Inc Derivado de triazol o su sal.
US20070224298A1 (en) 2006-03-23 2007-09-27 Talbott Shawn M Inhibiting 11(beta)-hsd1 with citrus flavonoids
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
ES2620657T3 (es) 2008-07-03 2017-06-29 Astellas Pharma Inc. Derivado de triazol o sal del mismo
EP2243494A1 (en) 2009-04-22 2010-10-27 OntoChem GmbH Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
UA112418C2 (uk) 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
CN104303060A (zh) * 2012-03-13 2015-01-21 艾伯维公司 选择或鉴别用于v1B拮抗剂治疗的受试者的方法
US9579322B2 (en) * 2014-07-09 2017-02-28 Eip Pharma, Llc Methods for treating neurologic disorders
CN107613986A (zh) 2015-04-07 2018-01-19 英特塞普特医药品公司 用于组合疗法的药物组合物
US10648506B2 (en) 2016-07-07 2020-05-12 Raul Mendoza Walking rig creeper interface
WO2018117063A1 (ja) 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
IL316907A (en) 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS

Similar Documents

Publication Publication Date Title
US20250205227A1 (en) Methods for administering corticosteroids
Seo Perioperative glucocorticoid management based on current evidence
JP5913136B2 (ja) 糖質コルチコイド感作物質としてのプロゲストーゲンの使用方法
Hilderson et al. Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options
JP2020520889A5 (cg-RX-API-DMAC7.html)
JP2013518908A5 (cg-RX-API-DMAC7.html)
MXPA04003266A (es) Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
WO2008087437A1 (en) Treatment of corticoid-resistant asthma or copd with p38 map kinase inhibit (eg. sb2035809)
JP2023542345A5 (cg-RX-API-DMAC7.html)
US20120245552A1 (en) Combination Therapy
RU2021113995A (ru) Способы введения кортикостероидов
Babaoğlu et al. Therapeutic mechanisms of glucocorticoids, their administration and chronotherapy
US20120309722A1 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
US11571412B2 (en) Thromboxane receptor antagonists in AERD/asthma
JP2025509955A5 (cg-RX-API-DMAC7.html)
Papi et al. Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage
Bissell et al. Glucocorticoids
TW201726145A (zh) 用於維持皮質類固醇滑液濃度之皮質類固醇調配物
Anandabaskar Adrenocorticosteroids and Their Antagonists
US3231468A (en) Dexamethasone-cyproheptadine oral antiflammatory compositions
US20070259841A1 (en) Combinations for the treatment of rheumatoid arthritis
Call Treatment of Adrenocorticosteroid Disorders
Fluticasone 21 CH2OH CH2OH CH2OH
Usta-Makkaoui et al. Hydrocortisone improves somnolence without hypotension in the postpartum period
CA2422991A1 (en) Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration